Literature DB >> 1373536

Morphological and functional changes of islets of Langerhans in FK506-treated rats.

Y Hirano1, S Fujihira, K Ohara, S Katsuki, H Noguchi.   

Abstract

FK506, a new immunosuppressant, caused glucose intolerance in rats given daily oral doses of 1, 5, or 10 mg/kg/day for 14 days, but did not induce hyperglycemia under normal feeding. Besides the glucose intolerance, insulin secretion was impaired and insulin levels in the pancreas were lowered. Histopathologically, there was vacuolation of the Langerhans islets in the animals given 10 mg/kg. After withdrawal of the drug, these changes in pancreatic function and morphology returned to normal within 2 weeks. The findings indicate that FK506 caused dose-dependent but reversible islet toxicity in rats.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373536     DOI: 10.1097/00007890-199204000-00033

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction.

Authors:  Nassir Rostambeigi; Ian R Lanza; Petras P Dzeja; Michael C Deeds; Brian A Irving; Honey V Reddi; Pranathi Madde; Song Zhang; Yan W Asmann; Jarett M Anderson; Jill M Schimke; K Sreekumaran Nair; Norman L Eberhardt; Yogish C Kudva
Journal:  Transplantation       Date:  2011-03-27       Impact factor: 4.939

2.  Pancreatic islet transplantation for diabetes.

Authors:  R M Jindal
Journal:  Postgrad Med J       Date:  1994-09       Impact factor: 2.401

3.  Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells.

Authors:  J B Redmon; L K Olson; M B Armstrong; M J Greene; R P Robertson
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

Review 4.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

Review 5.  Post-transplant diabetes mellitus. The role of immunosuppression.

Authors:  R M Jindal; R A Sidner; M L Milgrom
Journal:  Drug Saf       Date:  1997-04       Impact factor: 5.606

6.  Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice.

Authors:  M F Crutchlow; M Yu; Y-S Bae; S Deng; D A Stoffers
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

7.  Differential influence of tacrolimus and sirolimus on mitochondrial-dependent signaling for apoptosis in pancreatic cells.

Authors:  Andrei Alexandru Constantinescu; Malak Abbas; Mohamad Kassem; Céline Gleizes; Guillaume Kreutter; Valerie Schini-Kerth; Ioan Liviu Mitrea; Florence Toti; Laurence Kessler
Journal:  Mol Cell Biochem       Date:  2016-06-25       Impact factor: 3.396

Review 8.  Clinical islet cell transplantation. Are we there yet?

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1998-12

Review 9.  Calcineurin inhibitors in pediatric renal transplant recipients.

Authors:  Guido Filler
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

10.  Npas4 Transcription Factor Expression Is Regulated by Calcium Signaling Pathways and Prevents Tacrolimus-induced Cytotoxicity in Pancreatic Beta Cells.

Authors:  Thilo Speckmann; Paul V Sabatini; Cuilan Nian; Riley G Smith; Francis C Lynn
Journal:  J Biol Chem       Date:  2015-12-09       Impact factor: 5.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.